MedTrace Logo

Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing

NCT00733473 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-12-20

No results posted yet for this study

Summary

The purpose of this study is to determine if adding nebulized budesonide to the systemic steroid for treatment of acute wheezing has any additive benefit in children who have hospitalized for acute wheezing.

Conditions

Interventions

DRUG

Budesonide 0.5 mg/ml nebules

Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days

DRUG

% 0.9 Saline solution

Children will receive 2 ml of nebulized saline 2 times a day up to 5 days

Sponsors & Collaborators

  • Kecioren Education and Training Hospital

    lead OTHER

Principal Investigators

  • C H Razi, MD · Kecioren Education and Training Hospital

  • C H Razi, MD · Kecioren Education and Training Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-12-31
Completion
2010-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00733473 on ClinicalTrials.gov